Takeda, Cell Genesys Ink $270 Million GVAX Deal For Prostate Cancer
Oncology, urology areas are important to the firm because of huge unmet needs, Takeda tells “The Pink Sheet” DAILY.
Oncology, urology areas are important to the firm because of huge unmet needs, Takeda tells “The Pink Sheet” DAILY.